US20160347787A1 - Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications - Google Patents

Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications Download PDF

Info

Publication number
US20160347787A1
US20160347787A1 US15/116,456 US201515116456A US2016347787A1 US 20160347787 A1 US20160347787 A1 US 20160347787A1 US 201515116456 A US201515116456 A US 201515116456A US 2016347787 A1 US2016347787 A1 US 2016347787A1
Authority
US
United States
Prior art keywords
recombinant polypeptides
bind
cex
medium
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/116,456
Other languages
English (en)
Inventor
Austen NG
Robert S. GRONKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Priority to US15/116,456 priority Critical patent/US20160347787A1/en
Assigned to BIOGEN MA INC. reassignment BIOGEN MA INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRONKE, ROBERT S., NG, Austen
Publication of US20160347787A1 publication Critical patent/US20160347787A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • glycosylation profile of a polypeptide can be affected by multiple factors including the type of production cell line, the growth conditions and the polypeptide sequence. Shiestl, M., et al. Nature Biotechnology 29(4):310 (2011).
  • the present invention provides a method for enriching the level of post-translational modification of recombinant polypeptides, comprising: contacting a composition which comprises an initial population of recombinant polypeptides having different levels of post-translational modification with a cation exchange chromatography (CEX) medium operated in a flow-through mode; wherein recombinant polypeptides that do not bind the CEX medium are separated from recombinant polypeptides that bind the CEX medium, and wherein the recombinant polypeptides that do not bind the CEX medium comprise a higher level of post-translational modification compared to the bound recombinant polypeptides.
  • CEX cation exchange chromatography
  • the present invention provides a method for enriching the level of post-translational modification of recombinant polypeptides, comprising:
  • the present invention provides a method for enriching the level of post-translational modification of recombinant polypeptides, comprising:
  • the present invention provides a method for enriching the level of post-translational modification of recombinant polypeptides, comprising:
  • the method further provides recovering the recombinant polypeptides that do not bind the CEX medium.
  • the post-translational modification is sialylation or gamma-carboxyglutamate (Gla) formation. In some embodiments, the post-translational modification is sialylation.
  • the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 0.5 and about 6 moles of sialic acid per mole of protein higher than that of the initial population of recombinant polypeptides. In some embodiments, the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 0.5 and about 4 moles of sialic acid per mole of protein higher than that of the initial population of recombinant polypeptides.
  • the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 5% and about 100% higher than that of the initial population of recombinant polypeptides. In some embodiments, the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 5% and about 40% higher than that of the initial population of recombinant polypeptides. In some embodiments, the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 12 and about 20 moles of sialic acid per mole of protein. In some embodiments, the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 14 and about 17 moles of sialic acid per mole of protein.
  • the total sialic acid content of the initial population of recombinant polypeptides is about 10 to about 14 moles of sialic acid per mole of protein. In some embodiments, the total sialic acid content of the initial population of recombinant polypeptides is about 13-14 moles of sialic acid per mole of protein.
  • the recombinant polypeptide comprises an Fc domain. In some embodiments, the recombinant polypeptide comprises an antibody.
  • the recombinant polypeptide comprises an Fc fusion polypeptide comprising a ligand binding domain of a receptor.
  • the receptor is a TNF receptor.
  • the recombinant polypeptide is etanercept.
  • the recombinant polypeptide comprises a clotting factor.
  • the recombinant polypeptide is a monomer-dimer hybrid.
  • clotting factors include Factor VII (FVII), FVIIa, Factor VIII (FVIII), Factor IX (FIX), or FIXa (FIX).
  • FVIII can be full-length FVIII or B-domain deleted FVIII.
  • FVIII can be single chain FVIII or dual chain FVIII.
  • the contacting occurs at a load ratio between about 30 and about 100 mg total protein/ml CEX medium. In some embodiments, the contacting occurs at a load ratio between about 33 and about 54 mg total protein/ml CEX medium. In some embodiments, the contacting occurs at a load ratio of at least about 41 mg total protein/ml CEX medium.
  • the contacting occurs at a pH between about 4 and about 7. In some embodiments, the contacting occurs at a pH between about 5 and about 6. In some embodiments, the contacting occurs at a pH between about 5.5 and about 5.8 In some embodiments, the contacting occurs at a pH of at least about 5.6.
  • the contacting occurs at a conductivity between about 8 and about 12 mS/cm. In some embodiments, the contacting occurs at a conductivity of between about 9.5 and about 11 mS/cm. In some embodiments, the contacting occurs at a conductivity of at least about 10 mS/cm.
  • the recombinant polypeptides that do not bind the CEX medium comprise about 25% to about 80% of the initial population of recombinant polypeptides. In some embodiments, the recombinant polypeptides that do not bind the CEX medium comprise about 55% to about 80% of the initial population of recombinant polypeptides.
  • the CEX medium comprises one of the following ligands: sulfoethyl; sulphopropyl; sulfopropyl; CH 2 —SO 3 ⁇ ; CH 2 CH 2 CH 2 SO 3 ⁇ ; SO 3 ⁇ ; or CH 2 —COO ⁇ .
  • the CEX medium comprises a sulfoethyl ligand.
  • the CEX medium comprises a binding capacity of between about 120 and about 160 mg lysozyme/ml resin.
  • the recombinant polypeptide is produced by a eukaryotic host cell.
  • the eukaryotic host cell is a mammalian host cell.
  • the contacting is performed at a manufacturing scale.
  • the composition further comprises at least one impurity.
  • impurities include a DNA, RNA, lipid or protein.
  • the impurity comprises a protein.
  • the protein impurities include a truncated form of the recombinant polypeptide, an aggregated form of the recombinant polypeptide, or a misfolded form of the recombinant polypeptide.
  • the method provides a final composition comprising the recombinant polypeptides that do not bind the CEX medium, wherein the final composition comprises less impurities than the composition that comprised the initial population of polypeptides.
  • FIG. 1 illustrates a SE Hicap Chromatogram for the enrichment of sialylated etanercept.
  • the load ratio was 31 mg/ml, the load pH was 5.6, and the load conductivity was 10 mS/cm.
  • the product yield was 67%, and the total sialic acid of the product was 15 moles of sialic acid/mole of protein.
  • Peak 1 is composed of clipped etanercept.
  • Peak 2 is composed of native etanercept.
  • Peak 3 is composed of misfolded etanercept.
  • FIG. 2 illustrates a comparison of the TSA enrichment of etanercept by various CEX resins (SE Hicap, SP Sepharose, SP Sepharose XL, Nuvia S, Eshmuno, GigaCap S, and GigaCap CM). The results were normalized to 50% product yield.
  • FIG. 3 illustrates a comparison of the impurities removed from a composition comprising etanercept by various CEX resins (SE Hicap, SP Sepharose, SP Sepharose XL, Nuvia S, Eshmuno, GigaCap S, and GigaCap CM). The results were normalized to 50% product yield.
  • the present invention is directed to methods of enriching the level of post-translational modifications of recombinant polypeptides through the use of a chromatography medium.
  • the chromatography medium is an ion exchange chromatography medium utilized in a flow-through mode of operation.
  • a or “an” entity refers to one or more of that entity; for example, “a nucleotide sequence,” is understood to represent one or more nucleotide sequences.
  • the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.
  • protein or “polypeptide” refers to a polymer of two or more of the natural amino acids or non-natural amino acids.
  • Polypeptides may be either monomers or multimers.
  • a protein of the invention is a dimer.
  • a dimeric polypeptide of the invention may comprise two polypeptide chains or may consist of one polypeptide chain (e.g., in the case of a scFc molecule).
  • the dimers of the invention are homodimers, comprising two identical monomeric subunits or polypeptides (e.g., two identical Fc moieties or two identical biologically active moieties).
  • the dimers of the invention are heterodimers, comprising two non-identical monomeric subunits or polypeptides (e.g., comprising two different clotting factors or portions thereof or one clotting factor only). See, e.g., U.S. Pat. No. 7,404,956, incorporated herein by reference in its entirety.
  • “Recombinantly expressed polypeptide” and “recombinant polypeptide” refer to a polypeptide expressed from a host cell that has been genetically engineered to express that polypeptide.
  • the recombinantly expressed polypeptide can be identical or similar to polypeptides that are normally expressed in the mammalian host cell.
  • the recombinantly expressed polypeptide can also foreign to the host cell, i.e. heterologous to peptides normally expressed in the mammalian host cell.
  • the recombinantly expressed polypeptide can be chimeric in that portions of the polypeptide contain amino acid sequences that are identical or similar to polypeptides normally expressed in the mammalian host cell, while other portions are foreign to the host cell.
  • polypeptide that is expressible in a host cell may be produced in accordance with the present invention.
  • the polypeptide may be expressed from a gene that is endogenous to the host cell, or from a gene that is introduced into the host cell through genetic engineering.
  • the polypeptide may be one that occurs in nature, or may alternatively have a sequence that was engineered or selected by the hand of man.
  • An engineered polypeptide may be assembled from other polypeptide segments that individually occur in nature, or may include one or more segments that are not naturally occurring.
  • Polypeptides that may desirably be expressed in accordance with the present invention will often be selected on the basis of an interesting biological or chemical activity.
  • the present invention may be employed to express any pharmaceutically or commercially relevant enzyme, receptor, antibody, hormone, regulatory factor, antigen, binding agent, etc. . . . .
  • Polypeptides that are “variants” of another peptide may have one or more mutations relative to the starting polypeptide, e.g., one or more amino acid residues which have been substituted with another amino acid residue or which has one or more amino acid residue insertions or deletions.
  • the polypeptide comprises an amino acid sequence which is not naturally occurring. Such variants necessarily have less than 100% sequence identity or similarity with the starting polypeptide.
  • the variant will have an amino acid sequence from about 75% to less than 100% amino acid sequence identity or similarity with the amino acid sequence of the starting polypeptide, for example, from about 80% to less than 100%, from about 85% to less than 100%, from about 90% to less than 100% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) and from about 95% to less than 100%, e.g., over the length of the variant molecule.
  • a “fusion” or “chimeric” protein comprises a first amino acid sequence linked to a second amino acid sequence with which it is not naturally linked in nature.
  • the amino acid sequences which normally exist in separate proteins can be brought together in the fusion polypeptide, or the amino acid sequences which normally exist in the same protein can be placed in a new arrangement in the fusion polypeptide, e.g., fusion of a Factor VIII domain of the invention with an Ig Fc domain.
  • a fusion protein is created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship.
  • a chimeric protein can further comprises a second amino acid sequence associated with the first amino acid sequence by a covalent, non-peptide bond or a non-covalent bond.
  • aggregates refers to polypeptide aggregates. It encompasses multimers (such as dimers, tetramers or higher order aggregates) of the recombinant polypeptide to be purified and may result, e.g., in high molecular weight aggregates.
  • chromatography refers to any kind of technique which separates a recombinant polypeptide of interest from other molecules present in a mixture. Usually the recombinant polypeptide of interest is separated from other molecules as a result of differences in binding affinity.
  • binding means exposing the molecule to chromatography resin under appropriate conditions (e.g. pH/conductivity) such that the molecule is reversibly immobilized in or on the chromatography resin by virtue of ligand-protein interactions.
  • appropriate conditions e.g. pH/conductivity
  • Non-limiting examples include ionic interactions between the molecule and a charged group or charged groups of the ion exchange material and an immunoglobulin.
  • flow-through refers to a product separation technique in which at least one product (e.g., a recombinant polypeptide with specific post-translational modifications) contained in a sample is intended to flow-through a chromatographic resin or media, while at least one potential contaminant or impurity binds to the chromatographic resin or media.
  • product e.g., a recombinant polypeptide with specific post-translational modifications
  • chromatography resin chromatography media
  • chromatography medium refers to any kind of solid phase which separates a recombinant polypeptide of interest from other molecules present in a mixture.
  • the recombinant polypeptide of interest is separated from other molecules as a result of differences in binding affinity between the other molecules in the mixture and the recombinant polypeptide of interest.
  • use of any known, or subsequently disclosed or developed, chromatography media or matrix are examples of any known, or subsequently disclosed or developed, chromatography media or matrix.
  • Examples, without limitation, of such media comprise: ion exchange media; anion exchange media; cation exchange media; hydroxyapatite media; hydrophobic interaction chromatography media; antibody-affinity media (e.g., Protein-A or variants thereof); immunoglobulin Fc-region affinity media (e.g., Fc-receptor affinity media); and, ligand-affinity media; receptor-affinity media; and mixed-mode media.
  • ion exchange media e.g., Protein-A or variants thereof
  • immunoglobulin Fc-region affinity media e.g., Fc-receptor affinity media
  • ligand-affinity media ligand-affinity media
  • receptor-affinity media e.g., and mixed-mode media.
  • ion-exchange and ion-exchange chromatography are used to refer to a chromatographic process in which a recombinant polypeptide of interest interacts or does not interact with a charged compound linked (such as by covalent attachment) to a solid phase ion exchange material such that the recombinant polypeptide of interest interacts non-specifically with the charged compound more or less than other recombinant polypeptides or impurities in the mixture.
  • the contaminant in the mixture elutes from a column of the ion exchange material faster or slower than the recombinant polypeptide of interest or are bound to or excluded from the resin relative to the recombinant polypeptide of interest.
  • Ion-exchange chromatography specifically includes cation exchange, anion exchange, and mixed mode ion exchange chromatography.
  • pI or “isoelectric point” of a polypeptide refer to the pH at which the polypeptide's positive charge balances its negative charge, pI can be calculated from the net charge of the amino acid residues or sialic acid residues of attached carbohydrates of the polypeptide or can be determined by isoelectric focusing.
  • ion exchange material refers to a solid phase that is negatively charged (i.e., a cation exchange resin) or positively charged (i.e., an anion exchange resin).
  • the charge may be provided by attaching one or more charged ligands to the solid phase, e.g., by covalent linking.
  • the charge may be an inherent property of the solid phase (e.g., as is the case for silica, which has an overall negative charge).
  • anion exchange resin refers to a solid phase which is positively charged, e.g., having one or more positively charged ligands, such as quaternary amino groups, attached thereto.
  • commercially available anion exchange resins include DEAE cellulose, QAE SEPHADEXTM and FAST Q SEPHAROSETM (Pharmacia).
  • Anion exchange chromatography can bind the target molecule (e.g., an Fc region containing target protein) followed by elution or can predominately bind the impurities while the target molecule “flows through” the column.
  • cation exchange resin refers to a solid phase which is negatively charged, and which thus has free cations for exchange with cations in an aqueous solution passed over or through the solid phase.
  • a negatively charged ligand attached to the solid phase to form the cation exchange resin may, e.g., be a carboxylate or sulfonate.
  • cation exchange chromatography can be performed under conditions in which the resin bind the target molecule (e.g., an Fc region containing target protein) followed by elution (cation exchange bind and elution chromatography or “CIEX”).
  • CEX can be run in a mode which it predominately binds the impurities while the target molecule “flows through” the column (cation exchange flow-through chromatography).
  • Commercially available CEX resins include Fractogel SE Hicap, GE SPXL, GE SP Sepharose, Millipore Eshmuno S, Tosoh Gigacap CM, Tosoh Gigacap S-650, or BioRad Nuvia S.
  • the phrase “cation exchange resin” or “CEX” also refers to a mixed-mode resin that is partially or entirely operated in cation-exchange mode of chromatography.
  • Commercially available mixed-mode resins include Capto MMC.
  • the purification method disclosed herein utilizes a cation exchange chromatography step which is performed in a flow-through mode.
  • the present invention utilizes a “flow-through” mode of operation wherein a recombinant polypeptide is allowed to contact a chromatography medium (or other matrix).
  • a recombinant polypeptide having a selected characteristic preferentially does not bind to the chromatography medium (or other matrix) while recombinant polypeptides (as well as other impurities) not having the selected characteristic, or having less of the selected characteristic (such as a recombinant polypeptide having a lower overall net negative charge or a lower sialic acid content) binds to the medium (or matrix).
  • the flow-through, containing the enriched recombinant polypeptide is recovered.
  • the recombinant polypeptide mixture obtained is enriched with a higher concentration of product having the selected (target) characteristic compared to the composition containing the initial population of recombinant polypeptides prior to contacting with the chromatography medium.
  • the present invention is directed to selectively enriching recombinant polypeptides wherein the selected or desired product characteristic is that of having increased or enhanced overall (total) levels of sialic acid content.
  • a recombinant polypeptide with increased total sialic acid content is obtained by contacting a composition that contains a population of exchange chromatography medium (e.g., SE Hicap) with a mixture of the recombinant polypeptide.
  • Undesired products e.g., product with a lower sialic acid content, and other impurities
  • the selected product with high sialic acid content flows through the column and is recovered.
  • Methods of the present invention can be adapted and applied to the separation/purification of recombinant polypeptides based on any number of physical, biological, and/or chemical characteristics.
  • product isoforms may be selectively separated on the basis of charge and/or hydrophobicity by using appropriate adsorbents (such as, for example, strong or weak cation exchange resins for charge based separations and hydrophobic adsorbents for separations based on hydrophobicity).
  • adsorbents such as, for example, strong or weak cation exchange resins for charge based separations and hydrophobic adsorbents for separations based on hydrophobicity.
  • methods of the invention may be applied using mixed-mode chromatography (mixed-mode media) for separations based on two orthogonal product attributes (e.g., charge and hydrophobicity).
  • the invention relates to a method for enriching, increasing, enhancing, or augmenting the level of post-translational modification of recombinant polypeptides comprising: contacting a composition which comprises an initial population of recombinant polypeptides having different levels of post-translational modification with a cation exchange chromatography (CEX) medium operated in a flow-through mode; wherein recombinant polypeptides that do not bind the CEX medium are separated from recombinant polypeptides that bind the CEX medium, and wherein the recombinant polypeptides that do not bind the CEX medium comprise a higher or increased level of post-translational modification compared to the bound recombinant polypeptides.
  • a composition which comprises an initial population of recombinant polypeptides having different levels of post-translational modification with a cation exchange chromatography (CEX) medium operated in a flow-through mode; wherein recombinant polypeptides that do
  • the recombinant polypeptides that do not bind the CEX medium are more negatively charged than the polypeptides or other impurities that bind the CEX resin. In some embodiments, the invention further comprises recovering the recombinant polypeptides that do not bind the CEX medium.
  • recombinant polypeptides with higher levels of specific post-translational modifications are separated from recombinant polypeptides with lower levels of post-translational modifications through the use of a CEX medium operated in flow-through mode.
  • Separating refers to increasing the degree of purity of a recombinant polypeptide of interest from a composition or sample comprising the polypeptide and one or more impurities or contaminants.
  • the recombinant polypeptide of interest is separated from the other polypeptides or impurities in the composition through the use of charge.
  • the recombinant polypeptide of interest is more negatively charged than other polypeptides or impurities in the composition such that the recombinant polypeptide of interest does not bind to the CEX medium operated in flow-through mode.
  • the degree of purity of the recombinant polypeptide of interest is increased by removing (completely or partially) at least one impurity from the composition.
  • the post-translational modification is sialylation or gamma-carboxyglutamate (Gla) formation.
  • the post-translational modification is sialylation.
  • Sialylation is the final step of human glycosylation.
  • Total sialic residue refers to the total number of sialic residues on a given recombinant polypeptide.
  • the sialylation of a protein is critical to protein function, as the in vivo biological activity of glycosylated proteins is known to be dependent on the number of sialic acid units per molecule. Shiestl, M., et al. Nature Biotechnology 29(4):310 (2011).
  • the loss of sialic acid frequency leads to reduced glycoprotein solubility and reduced circulatory half-life.
  • the glycosylation profile of a polypeptide can be affected by many factors including the type of production cell line, the growth conditions, and the polypeptide sequence. Shiestl, M., et al. Nature Biotechnology 29(4):310 (2011).
  • the total sialic acid content of the recombinant polypeptide is between about 0.5 and about 6, between about 1 and about 4, or between about 1 and about 3 moles of sialic per mole of protein higher than that of the initial population of recombinant polypeptides. In some embodiments, the total sialic acid content of the recombinant polypeptide is between about 0.6 and about 2.7 moles of sialic per mole of protein higher than that of the initial population of recombinant polypeptides.
  • the total sialic acid content of the recombinant proteins is at least about 0.5, at least about 1.0, at least about 1.5, at least about 2.0, at least about 2.5, at least about 3.0, at least about 3.5, at least about 4.0, at least about 4.5, at least about 5.0, at least about 5.5, or at least about 6.0 moles of sialic per mole of protein higher than that of the initial population of recombinant polypeptides.
  • the total sialic content of the recombinant polypeptides that do not bind the CEX medium is between about 5% and about 100%, between about 5% and about 90%, between about 5% and about 80%, between about 5% and about 70%, between about 5% and about 60%, between about 5% and about 50%, and between about 5% and about 40% higher than that of the composition containing the initial population of recombinant polypeptides.
  • the total sialic content of the recombinant polypeptides that do not bind the CEX medium is at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99% or at least about 100% higher than that of the composition containing the initial population of recombinant polypeptides.
  • the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 13 and about 20, between about 13.5 and about 19, between about 14 and about 18, between about 14 and about 17, or between about 14 and about 16.5 moles of sialic acid per mole of protein. In some embodiments, the total sialic acid content of the recombinant polypeptides that do not bind the CEX medium is between about 14.1 and about 16.2.
  • the total sialic content of the initial content of the initial population of recombinant polypeptides is between about 10 and about 14, between about 10.5 and about 14, between about 11 and about 14, between about 11.5 and about 14, between about 12 and about 14, between about 12.5 and about 14, or between about 13 and about 14 moles of sialic acid per mole of protein.
  • the total sialic acid content of the initial population of recombinant polypeptides is at least about 10, at least about 10.5, at least about 11, at least about 11.5, at least about 12, at least about 12.5, at least about 13, at least about 13.5 or at least about 14 moles of sialic acid per mole of protein.
  • the total sialic acid content of the initial population of recombinant polypeptides is at least about 13.5 moles of sialic acid per mole of protein.
  • the post-translational modification is gamma-carboxyglutamate (Gla) formation.
  • the carboxylation/gamma-carboxyglutamic (GLA) domain is a Vitamin-K dependent domain.
  • Vitamin K mediates the carboxylation of glutamate residues to form gamma-carboxyglutamate (Gla).
  • Gla plays a key role in calcium binding, and has been found to be critical for specific conformational transitions in clotting factor proteins. Freedman, S. J. et al., J. Biol. Chem. 271(27): 16227-36 (1996).
  • the Gla content of the recombinant polypeptides that do not bind the CEX medium is between about 5% and about 100%, between about 5% and about 90%, between about 5% and about 80%, between about 5% and about 70%, between about 5% and about 60%, between about 5% and about 50%, and between about 5% and about 40% higher than that of the initial population of recombinant polypeptides.
  • the total Gla content of the recombinant polypeptides that do not bind the CEX medium is between about 5% and about 100%, between about 5% and about 90%, between about 5% and about 80%, between about 5% and about 70%, between about 5% and about 60%, between about 5% and about 50%, and between about 5% and about 40% higher than that of the initial population of recombinant polypeptides.
  • a chromatography medium in “flow-through” mode of operation is utilized to enrich a composition of recombinant polypeptides having a specific post-translational modification.
  • the load ratio describes the total amount of the composition that is contacting the chromatography medium per volume of medium. If the load ratio is too high, then, in the case of a column run in flow-through mode, some impurities may not bind the medium.
  • the contacting of the composition with the medium occurs at a load ratio of at least about 30 mg total protein/ml CEX medium, at least about 35 mg total protein/ml CEX medium, at least about 40 mg total protein/ml CEX medium, at least about 45 mg total protein/ml CEX medium, at least about 50 mg total protein/ml CEX medium, at least about 55 mg total protein/ml CEX medium, at least about 60 mg total protein/ml CEX medium, at least about 70 mg total protein/ml CEX medium, at least about 80 mg total protein/ml CEX medium, at least about 90 mg total protein/ml CEX medium, at least about 100 mg total protein/ml CEX medium, at least about 110 mg total protein/ml CEX medium, at least about 120 mg total protein
  • the contacting occurs at a load ratio of 41 mg total protein/ml CEX medium. In some embodiments, the contacting of the composition with the medium occurs at a load ratio of between about 30 mg total protein/ml CEX medium and about 150 mg total protein/ml CEX medium, between about 30 mg total protein/ml CEX medium and 125 mg total protein/ml CEX medium, between about 30 mg total protein/ml CEX medium and 100 mg total protein/ml CEX medium, between about 30 mg total protein/ml CEX medium and 75 mg total protein/ml CEX medium, between about 30 mg total protein/ml CEX medium and 60 mg total protein/ml CEX medium, or between about 33 mg total protein/ml CEX medium and 54 mg total protein/ml CEX medium.
  • the pH of the contacting step is critical because it determines which charged molecules will bind the column and which will not bind.
  • the contacting of the composition with the medium occurs at a pH of at least about 3, at least about 4, at least about 5, at least about 5.5, at least about 6, at least about 6.5, at least about 7, at least about 8 or at least about 9.
  • the contacting occurs at a pH of 5.6.
  • the contacting of the composition with the medium occurs at a pH between about 3 and about 9, between about 4 and about 8, between about 4 and about 7, between about 5 and about 7, between about 5 and about 6, or between about 5.5 and about 5.8.
  • the contacting of the composition with the medium occurs at a conductivity of at least about 8 mS/cm, at least about 8.5 mS/cm, at least about 9 mS/cm, at least about 10 mS/cm, at least about 10.5 mS/cm, at least about 11 mS/cm, at least about 11.5 mS/cm, at least about 12 mS/cm, at least about 12.5 mS/cm, or at least about 13 mS/cm. In some embodiments the contacting occurs at a conductivity of 10 mS/cm.
  • the contacting occurs at a conductivity of between about 8 mS/cm and about 12 mS/cm, between about 8.5 mS/cm and 11.5 mS/cm, between about 9 mS/cm and about 11.5 mS/cm, between about 9 mS/cm and about 11 mS/cm, or between about 9.5 mS/cm and 11 mS/cm.
  • the chromatography medium is ion exchange media; anion exchange media; cation exchange media; hydroxyapatite media; hydrophobic interaction chromatography media; antibody-affinity media (e.g., Protein-A or variants thereof); immunoglobulin Fc-region affinity media (e.g., Fc-receptor affinity media); and, ligand-affinity media; receptor-affinity media; or mixed-mode media.
  • the chromatography medium is a CEX resin.
  • Embodiments of the invention include use of any known, or subsequently disclosed or developed, CEX chromatography media or matrix.
  • the CEX resin is a Fractogel SE Hicap, GE SPXL, GE SP Sepharose, Millipore Eshmuno S, Tosoh Gigacap CM, Tosoh Gigacap S-650, BioRad Nuvia S, or Capto MMC.
  • the CEX medium comprises a ligand that is sulfoethyl; sulphopropyl; sulfopropyl; CH 2 —SO 3 ; CH 2 CH 2 CH 2 SO 3 ⁇ ; SO 3 ⁇ ; CH 2 —COO ⁇ ; or a multimodal weak cation exchanger.
  • the CEX medium comprises a matrix that is: crosslinked polymethacrylate, 6% cross-linked agarose with dextran surface extenders, agarose, surface grafted rigid polyvinyl ether hydrophilic polymer, or highly cross-linked agarose.
  • the CEX medium is any known matrix.
  • the CEX medium comprises a sulfoethyl ligand.
  • the CEX resin is Fractogel SE Hicap.
  • the CEX medium comprises a binding capacity or ligand capacity of between about 100 and about 200 mg lysozyme/ml resin, between about 110 and 190 mg lysozyme/ml resin, between about 120 and about 180 mg lysozyme/ml resin, between about 120 and about 170 mg lysozyme/ml resin, between about 120 and about 160 mg lysozyme/ml resin, or between about 125 and 160 mg lysozyme/ml resin.
  • the ion exchange rate between the medium and the composition increases as the temperature increases. Temperature can also affect the selectivity of the column.
  • the temperature during the contacting of the composition with the medium is between about 16 and about 26° C., between about 18 and about 24° C., or between about 20 and about 23° C.
  • the temperature during the contacting of the composition with the medium is at least about 15° C., at least about 16° C., at least about 17° C., at least about 18° C., at least about 19° C., at least about 20° C., at least about 21° C., at least about 22° C., at least about 23° C., at least about 24° C., at least about 25° C., at least about 26° C. or at least about 30° C.
  • the temperature during the contacting of the composition with the medium is about 22° C.
  • the process flow rate is between about 75 cm/hr and about 150 cm/hr, between about 100 cm/hr and about 150 cm/hr, or between about 120 cm/hr and about 150 cm/hr.
  • the process flow rate is at least about 75 cm/hr, at least about 80 cm/hr, at least about 90 cm/hr, at least about 100 cm/hr, at least about 110 cm/hr, at least about 115 cm/hr, at least about 120 cm/hr, at least about 125 cm/hr, at least about 130 cm/hr, at least about 135 cm/hr, at least about 140 cm/hr, or at least about 150 cm/hr. In some embodiments, the process flow rate is about 125 cm/hr.
  • Embodiments of the invention include methods for recovering a selected recombinant polypeptide at a manufacturing scale; including a method wherein the selected recombinant polypeptide is a therapeutically useful or beneficial compound.
  • the composition containing the initial population of recombinant polypeptides contains only the recombinant polypeptide of interest with differing levels of the selected characteristic. In some embodiments, the composition containing the initial population of recombinant polypeptides also contains additional polypeptides that have a different amino acid sequence than the recombinant polypeptide of interest. In some embodiments, the additional polypeptides are recombinant. In some embodiments, the composition containing the initial population of recombinant polypeptides also contains impurities. In some embodiments, the impurity is a DNA, RNA, lipid or protein molecule.
  • the impurity is a truncated form of the recombinant polypeptide, an aggregated form of the recombinant polypeptide, or a misfolded form of the recombinant polypeptide.
  • the composition containing the recombinant polypeptide that does not bind the CEX medium has less impurities that the composition that contained the initial population of recombinant polypeptides.
  • the composition containing the recombinant polypeptide that does not bind the CEX medium has at least about 5%, at least about 10%, at least about 25%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99% less impurities than the composition that contained the initial population of recombinant polypeptides.
  • the recombinant polypeptides that do not bind the CEX medium are between about 10% and about 90%, between about 20% and about 80%, between about 30% and about 80%, between about 40% and about 80%, between about 50% and about 80%, or between about 55% and about 80% of the recombinant polypeptides of the composition comprising the initial population. In some embodiments, the recombinant polypeptides that do not bind the CEX medium are between about 55% and about 80% of the recombinant polypeptides of the composition comprising the initial population.
  • product may be selectively enriched/separated, for example, based on peak product pI values wherein, for example, higher pI isoforms may be separated from lower pI product isoforms on a cation exchange adsorbent.
  • the recombinant polypeptides that do not bind the CEX medium are subjected to one or more further purification steps following the CEX chromatography.
  • the composition containing the initial population of recombinant polypeptides is subjected to one or more purification steps prior to the contacting with the CEX medium.
  • the pH and the conductivity of the composition with the initial population of recombinant polypeptides are adjusted prior to contacting the composition with the CEX medium.
  • the pH of the recombinant polypeptides that do not bind the CEX medium is adjusted following the contacting with the CEX medium.
  • Embodiments of the invention are useful for obtaining highly homogeneous mixtures of a wide variety of recombinant polypeptides with specific levels of post-translational modifications.
  • Some examples of such recombinant polypeptides include, without limitation, proteins and protein fragments (i.e., full-length and partial length polypeptides/peptides), antibodies (immunoglobulins), heterologous fusion proteins, etc. . . . .
  • the polypeptide is a dimer.
  • the polypeptide is a monomer.
  • the recombinant polypeptide is a non-immunoglobulin proteins (or fragments thereof) fused with an immunoglobulin (or domains, regions, of fragments thereof).
  • the recombinant polypeptide comprises an Fc domain.
  • the recombinant polypeptide comprises an antibody.
  • methods of the invention are used for separation/purification of a recombinant polypeptide comprising an extracellular receptor ligand-binding domain linked (i.e., “fused”) with the Fc-region of an immunoglobulin (such as the Fc region of an IgG molecule). Examples of Fc-fusion proteins can be seen in Table 1.
  • the recombinant polypeptide is an Fc fusion polypeptide comprising a ligand binding domain of a receptor.
  • the receptor is a Tumor necrosis factor (“TNF”) receptor.
  • the recombinant polypeptide is etanercept.
  • Etanercept is a dimeric recombinant therapeutic glycoprotein, which consisting of the extracellular ligand binding portion of the human 75 kilodalton human tumor necrosis factor receptor linked to the constant region (Fc) of human IgG1.
  • Fc constant region
  • Etanercept is as a TNF inhibitor, an acts as a decoy receptor that binds to TNF. Zalevsky, J. et al., J. Immunol. 179(3): 1872-83. Etanercept acts in a similar function to naturally occurring soluble TNF receptors. However, as etanercept is a fusion protein, it has a greater half-life in the bloodstream, and therefore has a longer impact than a naturally occurring receptor. Madhusudan, S. J. Clin Oncol. 23(25): 5950-9. The Fc portion of the fusion protein transiently anchors to Fc receptors expressed on the surface of endothelial cells, which delays the degradation and increases the half-life of etanercept.
  • Etanercept requires N-glycosylation for biological activity.
  • Glycosylated proteins are complex molecules and even a well-controlled product may consist of several hundred or more glycoforms with different glycan compositions on the same amino acid sequence.
  • the in vivo biological activity of glycosylated proteins is known to be dependent on the number of sialic acid units per molecule, which is a result of the available sialylation sites, the antenniarity of the N-glycans and the completeness of sialylation. Shiestl, M., et al. Nature Biotechnology 29(4):310 (2011).
  • the recombinant polypeptide comprises a clotting factor.
  • the clotting factor is selected from Factor VII (FVII), FVIIa, Factor VIII (FVIII), Factor IX (FIX), or FIXa (FIX).
  • the FVIII is full-length FVIII or B-domain deleted FVIII.
  • the FVIII is single chain FVIII or dual chain FVIII.
  • the recombinant polypeptide is a monomer-dimer hybrid.
  • a monomer-dimer hybrid is a chimeric protein having a dimeric aspect and a monomeric aspect, wherein the dimeric aspect relates to the fact that it is comprised of two polypeptide chains each comprised of a portion of an immunoglobulin constant region, and wherein the monomeric aspect relates to the fact that only one of the two chains is comprised of a therapeutic biologically active molecule.
  • Monomer-dimer hybrids are described in detail is U.S. Pat. No. 7,404,956, which is incorporated herein by reference in its entirety.
  • Fractor VII refers to a coagulation factor protein synthesized in the liver and secreted into the blood as a single chain zymogen with a molecular weight of approximately 50 kDa. The FVII zymogen is converted into an activated form (FVIIa) by proteolytic cleavage. FVII is disclosed in U.S. Publ. No. 2011/0046061 and Int'l Publ. No. PCT/US2013/44842, each of which is incorporated herein by reference in its entirety.
  • Fractor VIII refers to a blood coagulation factor protein and species and sequence variants thereof that includes, but is not limited to, the 2351 amino acid single-chain precursor protein (with a 19-amino acid hydrophobic signal peptide), the mature 2332 amino acid factor VIII protein of approximately 270-330 kDa with the domain structure A1-A2-B-A3-C1-C2, as well as the circulating heterodimer of two chains that form as a result of proteolytic cleavage after R1648 of a heavy chain form composed of A1-A2-B (in the range of 90-220 kD) of amino acids 1-1648 (numbered relative to the mature FVIII form) and a light chain A3-C1-C2 of 80 kDa of amino acids 1649-2232, each of which is depicted schematically in FIG.
  • “Factor VIII” or “FVIII” also can be sequence variants that retain at least a portion of the biological activity of the native circulating protein, including truncated sequences, a sequence that includes heterologous amino acids, or a single chain FVIII (scFVIII) in which the heavy and light chains are covalently connected by a linker.
  • “FVIII” shall be any functional form of factor VIII molecule with the typical characteristics of blood coagulation factor VIII capable of in vivo or in vitro correction of human factor VIII deficiencies (e.g., hemophilia A). FVIII or sequence variants have been isolated, characterized, and cloned, as described in U.S. Pat. or Publ. Nos. U.S.
  • B domain of Factor VIII is the same as the B domain known in the art that is defined by internal amino acid sequence identity and sites of proteolytic cleavage by thrombin, e.g., residues Ser741-Arg1648 of full length human factor VIII.
  • the other human factor VIII domains are defined by the following amino acid residues: A1, residues Ala1-Arg372; A2, residues Ser373-Arg740; A3, residues Ser1690-Ile2032; C1, residues Arg2033-Asn2172; C2, residues Ser2173-Tyr2332.
  • the A3-C1-C2 sequence includes residues Ser1690-Tyr2332.
  • the remaining sequence, residues Glu1649-Arg1689, is usually referred to as the factor VIII light chain activation peptide.
  • the locations of the boundaries for all of the domains, including the B domains, for porcine, mouse and canine factor VIII are also known in the art.
  • the B domain of Factor VIII is deleted (“B domain deleted factor VIII” or “BDD FVIII”).
  • BDD FVIII An example of a BDD FVIII is REFACTO (recombinant BDD FVIII).
  • REFACTO recombinant BDD FVIII
  • a “B domain deleted factor VIII” may have the full or partial deletions disclosed in U.S. Pat. Nos. 6,316,226, 6,346,513, 7,041,635, 5,789,203, 6,060,447, 5,595,886, 6,228,620, 5,972,885, 6,048,720, 5,543,502, 5,610,278, 5,171,844, 5,112,950, 4,868,112, and 6,458,563, each of which is incorporated herein by reference in its entirety.
  • a B domain deleted factor VIII sequence of the present invention comprises any one of the deletions disclosed at col. 4, line 4 to col. 5, line 28 and examples 1-5 of U.S. Pat. No. 6,316,226 (also in U.S. Pat. No. 6,346,513).
  • a B domain deleted factor VIII of the present invention has a deletion disclosed at col. 2, lines 26-51 and examples 5-8 of U.S. Pat. No. 5,789,203 (also U.S. Pat. No. 6,060,447, U.S. Pat. No. 5,595,886, and U.S. Pat. No. 6,228,620).
  • a B domain deleted factor VIII has a deletion described in col. 1, lines 25 to col. 2, line 40 of U.S. Pat. No. 5,972,885; col. 6, lines 1-22 and example 1 of U.S. Pat. No. 6,048,720; col. 2, lines 17-46 of U.S. Pat. No. 5,543,502; col. 4, line 22 to col.
  • a B domain deleted factor VIII has a deletion of most of the B domain, but still contains amino-terminal sequences of the B domain that are essential for in vivo proteolytic processing of the primary translation product into two polypeptide chain, as disclosed in WO 91/09122, which is incorporated herein by reference in its entirety.
  • a B domain deleted factor VIII is constructed with a deletion of amino acids 747-1638, i.e., virtually a complete deletion of the B domain. Hoeben R. C., et al, J. Biol. Chem. 265 (13): 7318-7323 (1990), incorporated herein by reference in its entirety. A.
  • B domain deleted factor VIII may also contain a deletion of amino acids 771-1666 or amino acids 868-1562 of factor VIII.
  • Additional B domain deletions that are part of the invention include, e.g.: deletion of amino acids 982 through 1562 or 760 through 1639 (Toole et al., Proc. Natl. Acad. Sci. U.S.A. (1986) 83, 5939-5942)), 797 through 1562 (Eaton, et al. Biochemistry (1986) 25:8343-8347)), 741 through 1646 (Kaufman (PCT published application No.
  • Factor IX and “FIX,” as used herein, means functional Factor IX polypeptide in its normal role in coagulation, unless otherwise specified.
  • Factor IX includes variant polypeptides that are functional and the polynucleotides that encode such functional variant polypeptides.
  • Preferred Factor IX polypeptides are the human, bovine, porcine, canine, feline, and murine Factor IX polypeptides.
  • the full length polypeptide and polynucleotide sequences of Factor IX are known, as are many functional variants, e.g., fragments, mutants and modified versions.
  • Factor IX polypeptides include full-length Factor IX, full-length Factor IX minus Met at the N-terminus, full-length Factor IX minus the signal sequence, mature Factor IX (minus the signal sequence and propeptide), and mature Factor IX with an additional Met at the N-terminus.
  • Factor IX is preferably made by recombinant means (“recombinant Factor IX” or “rFIX”), i.e., it is not naturally occurring or derived from plasma.
  • FIX is disclosed in U.S. Publ. Nos. 2011/0046060 and 2013/0202595, each of which is incorporated herein by reference in its entirety.
  • the recombinant polypeptide is an antibody. In some embodiments, the recombinant polypeptide is a monoclonal antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the recombinant polypeptide is a chimeric antibody. In some embodiments, the recombinant polypeptide is any antibody disclosed in U.S. Pat. No. 7,300,773, which is incorporated herein by reference in its entirety.
  • the recombinant polypeptide is a receptor.
  • the antibody is a receptor tyrosine kinase.
  • the receptor is any receptor disclosed in U.S. Pat. No. 7,300,773, which is incorporated herein by reference in its entirety.
  • the recombinant polypeptide is a growth factor or other signaling molecule. In some embodiments the recombinant polypeptide is a G-protein coupled receptor. In some embodiments the recombinant polypeptide is any polypeptide disclosed in U.S. Pat. No. 7,300,773.
  • the recombinant polypeptide is produced by a host cell. In some embodiments, the recombinant polypeptide is produced by a eukaryotic host cell. In some embodiments, the recombinant polypeptide is produced by a mammalian host cell.
  • HCP host cell protein
  • Peak 1 clipped etanercept
  • TSA total sialic acid
  • a chromatography process was developed for the isolation/purification/enrichment of recombinant polypeptides with enhanced or increased levels of sialylation compared to recombinant polypeptides with decreased or lower levels of sialylation present in the same initial mixture.
  • the recombinant polypeptide utilized in this example is the TNFR-Fc fusion protein etanercept.
  • Highly sialylated forms of recombinant polypeptides can represent a highly desirable class of therapeutically advantageous protein isoforms.
  • the present example describes development of a robust process capable of enriching the content of recovered/isolated, highly sialylated forms of recombinant polypeptides while maintaining acceptable product recovery and yield. In this particular example, a process was developed wherein SE Hicap chromatography was used to recover/isolate highly sialylated forms of an Fc-fusion protein.
  • SE Hicap utilized in flow-through mode was selected primarily for its TSA enrichment potential, ability to reduce Peak 3 and aggregates, capability for robust DNA clearance, and ease of interface with the other process steps.
  • SE Hicap enriches TSA by electrostatically repelling the negatively-charged sialylated etanercept into the flow-through, while retaining the more positively-charged (lesser sialylated) protein when run at a pH below its pI. It was found that load pH, load conductivity, and loading ratio are all key and critical parameters for this column. Process temperature, process flow rate, and resin ligand capacity had negligible impact on yield and product attributes under the conditions studied and were judged to be non-key process parameters.
  • Load Material and Adsorbent All samples were frozen at ⁇ 70° C. and thawed at ambient temperature prior to initiating chromatography. For all of the experiments, the load pH was adjusted with 1 M acetic acid, 1 M citric acid, or 2.4 M Tris base. Then, the load conductivity was adjusted with 1 M NaCl in acetate or citrate buffer. RO/DI water was added if the load conductivity was too high.
  • Static binding capacity calculations were used to screen candidate CEX resins for their ability to bind protein. This was determined by buffer exchanging the candidate resins with equilibration buffer and then incubating the composition containing the Etanercept overnight with a known volume of candidate resins on a shaker. The mixtures of resin and protein were spun down and the supernatants were subsequently measured for A280. The resins with high static capacities were then packed in columns and further evaluated in bind/elute or flow-through mode. Product yield, aggregates, Peak 1, Peak 2, Peak 3, TSA, HCP, and DNA were measured to gauge separation performance. Resins with high capacities that had poor separation of product-related impurities during elution were further evaluated as a capture step, but eliminated as a polishing step. However, resins with low capacities that had good separation of impurities were further evaluated in flow-through mode, as was the case with SE Hicap.
  • SE Hicap was selected specifically for its ability to enrich TSA and remove aggregates, DNA, and some Peak 3 and HCP.
  • SE Hicap in flow-through mode had no challenges interfacing with previous and subsequent purification steps, while eliminating need for any intermediate step. It was determined that acetate buffer was the most optimal buffer to be used in this process.
  • a DoE (central composite) study was designed to characterize the load ratio, load conductivity, and load pH, while a second DoE (screening) was designed to characterize the process temperature, resin capacity, and process flow rate. Both DoE studies were designed using Design Expert (version 8.0.6). Load ratio, load conductivity, and load pH were chosen as variables in the first DoE because earlier experiments showed that they had an impact on product yield and product attributes. Process temperature, resin capacity, and process flow rate were assessed in a separate DoE because earlier studies showed that these parameters had minimal effect on product yield and product attributes.
  • Low load pH and low load conductivity decreased product yield, enriched TSA content, increased Peak 1 impurity, decreased aggregate level, and increased monomer content (Table 3, see also Table 4).
  • Load pH and load conductivity have an interaction in that a low load pH can offset the effects of high load conductivity on these outputs and vice versa.
  • Peak 2 level decreased by the amount that was increased in Peak 3 level (Table 3, see also Table 4). This showed that varying load conductivity and load pH can change the relative distribution of Peaks 1, 2, and 3.
  • a high load conductivity or high load pH decreased DNA clearance (Table 5).
  • load pH decreased DNA clearance to a greater extent than conductivity.
  • a high load pH also decreased HCP clearance (Table 5).
  • the negatively-charged acidic isoform was enriched at low conductivity and low pH, but reduced in concentration when the basic and main isoforms desorbed from the column at high conductivity or high pH (Table 5). Therefore, load pH and load conductivity have an interaction in that load pH can offset the effects of load conductivity on the isoforms.
  • the operating space for SE Hicap should have a load pH target of 5.6 with a range of 5.5-5.8, a load conductivity target of 10.0 mS/cm with a range of 9.5-11 mS/cm, and a load ratio target of 41 mg/mL resin with a range of 33-54 mg/mL resin.
  • These load conditions would ensure that the flow-through/wash pool have TSA levels of 15-16.5 mole/mole, aggregate levels of ⁇ 6%, Peak 1 levels of ⁇ 6%, DNA clearance of ⁇ 1.5 LRV, and a sufficient product yield of 55-80%.
  • the SE Hicap flow-through chromatography was successfully developed as the second purification step to enrich TSA levels to 15-16.5 mole/mole, decrease aggregates by ⁇ 12%, and reduce DNA by ⁇ 1.5 LRV, while maintaining high product recoveries of 55-75% (A280) under target operating conditions.
  • the recommended operating space for SE Hicap would have a load pH target of 5.6 ⁇ 0.2, a load conductivity target of 10.0 mS/cm with a range of 9.5-11 mS/cm, and a load ratio target of 41 mg/mL resin ⁇ 8 mg/mL resin based on DoE results.
  • Other process parameters such as process temperature, process flow rate, and resin capacity had negligible impact on product yield and product attributes.
  • the operating conditions necessary to enrich TSA while removing aggregates and/or misfolds was determined for other CEX resins.
  • the resins tested were: GE SPXL, GE SP Sepharose, Millipore Eshmuno S, Tosoh Gigacap CM, Tosoh Gigacap S-650, and BioRad Nuvia S.
  • the final operating conditions for each column can be seen below in Table 7:
  • FIG. 2 A comparison of the enrichment of TSA by each column, with the results normalized to 50% of product yield, can be seen in FIG. 2 .
  • FIG. 3 A comparison of the aggregates and misfolds removed by each column, with the results normalized to 50% of product yield, can be seen in FIG. 3 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Chemical Kinetics & Catalysis (AREA)
US15/116,456 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications Abandoned US20160347787A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/116,456 US20160347787A1 (en) 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461935728P 2014-02-04 2014-02-04
US15/116,456 US20160347787A1 (en) 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
PCT/US2015/014469 WO2015120056A1 (en) 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/014469 A-371-Of-International WO2015120056A1 (en) 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/718,116 Continuation US12018046B2 (en) 2014-02-04 2022-04-11 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Publications (1)

Publication Number Publication Date
US20160347787A1 true US20160347787A1 (en) 2016-12-01

Family

ID=52684642

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/116,456 Abandoned US20160347787A1 (en) 2014-02-04 2015-02-04 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US17/718,116 Active US12018046B2 (en) 2014-02-04 2022-04-11 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/718,116 Active US12018046B2 (en) 2014-02-04 2022-04-11 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Country Status (8)

Country Link
US (2) US20160347787A1 (de)
EP (1) EP3102589A1 (de)
JP (1) JP6609561B2 (de)
KR (3) KR102382402B1 (de)
AU (1) AU2015214245B2 (de)
IL (2) IL246912B (de)
NZ (1) NZ722391A (de)
WO (1) WO2015120056A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021006419A1 (en) * 2019-07-08 2021-01-14 Sam Chun Dang Pharm. Co., Ltd. Refining method of ophthalmic protein pharmaceutical
US12018046B2 (en) 2014-02-04 2024-06-25 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6621176B2 (ja) * 2016-01-22 2019-12-18 旭化成メディカル株式会社 タンパク質の精製方法
BR112020007823A2 (pt) * 2017-10-20 2020-10-27 Fred Hutchinson Cancer Research Center sistemas e métodos para produzir células b geneticamente modificadas para expressar anticorpos selecionados
JP2022550930A (ja) 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US5004804A (en) 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
EP0218712B1 (de) 1985-04-12 1992-02-26 Genetics Institute, Inc. Neue prokoagulierungsproteine
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
US7294481B1 (en) * 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
HUE033776T2 (en) 2004-11-12 2018-01-29 Bayer Healthcare Llc FVIII site-specific modification
KR100667860B1 (ko) * 2005-10-18 2007-01-11 주식회사 녹십자 고순도 사람 혈액응고 제9인자의 정제 방법
CN101679509A (zh) * 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
EP3441402A1 (de) 2007-10-30 2019-02-13 Genentech, Inc. Antikörperreinigung durch kationenaustauschchromatographie
RU2567811C2 (ru) * 2008-06-24 2015-11-10 Октафарма Аг Способ очистки фактора свертывания крови viii
MX2010014180A (es) * 2008-06-24 2011-02-15 Reddys Lab Inc Dr Purificacion de citocinas modificadas.
WO2010071208A1 (ja) * 2008-12-19 2010-06-24 武田薬品工業株式会社 抗体の精製方法
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CA2782424C (en) 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
WO2013009526A1 (en) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Method for purifying fc-fusion protein
US20150065689A1 (en) * 2012-04-10 2015-03-05 Dr. Reddy's Laboratories Limited Single step fractionation method
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018046B2 (en) 2014-02-04 2024-06-25 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2021006419A1 (en) * 2019-07-08 2021-01-14 Sam Chun Dang Pharm. Co., Ltd. Refining method of ophthalmic protein pharmaceutical

Also Published As

Publication number Publication date
KR102382402B1 (ko) 2022-04-01
KR20160117562A (ko) 2016-10-10
IL246912B (en) 2022-05-01
IL246912A0 (en) 2016-09-29
US12018046B2 (en) 2024-06-25
KR102567586B1 (ko) 2023-08-16
NZ722391A (en) 2022-12-23
JP6609561B2 (ja) 2019-11-20
JP2017505780A (ja) 2017-02-23
WO2015120056A1 (en) 2015-08-13
AU2015214245A1 (en) 2016-08-11
US20220306684A1 (en) 2022-09-29
KR20230136616A (ko) 2023-09-26
AU2015214245B2 (en) 2020-09-10
EP3102589A1 (de) 2016-12-14
KR20220044391A (ko) 2022-04-07
IL292150A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
US12018046B2 (en) Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
US11168110B2 (en) Method for separation of monomeric polypeptides from aggregated polypeptides
DK2729482T3 (en) PROCEDURE FOR CLEANING FC-FUSION PROTEIN
US20190300601A1 (en) Correctly folded etanercept in high purity and excellent yield
EP3048899B1 (de) Verfahren zur virusinaktivierung auf einer säule
US10221210B2 (en) Polypeptide separation methods
US20120021484A1 (en) Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins
US20220259291A1 (en) Antibody purification methods and compositions thereof
RU2698671C2 (ru) КОЛИЧЕСТВЕННАЯ ОЦЕНКА НЕПРАВИЛЬНО СВЕРНУТОГО TNFR2:Fc
KR20220143676A (ko) 정제 방법
WO2021181414A1 (en) METHOD OF SEPARATING HIGH-MOLECULAR WEIGHT AGGREGATES OF AN Fc-FUSION PROTEIN

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOGEN MA INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NG, AUSTEN;GRONKE, ROBERT S.;REEL/FRAME:039898/0042

Effective date: 20160913

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION